{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T11:57:35Z","timestamp":1789732655028,"version":"4.0.1"},"reference-count":90,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["advancessurgery.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advances in Surgery"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.yasu.2025.04.011","type":"journal-article","created":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T16:03:43Z","timestamp":1749744223000},"page":"47-75","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["What Is the Role of Irreversible Electroporation for Pancreatic Cancer?"],"prefix":"10.1016","volume":"59","author":[{"suffix":"II","given":"Robert C.G.","family":"Martin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher D.","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.yasu.2025.04.011_bib1","first-page":"486","article-title":"Long-term survival in metastatic pancreatic cancer. A case report and review of the literature","volume":"7","author":"Spinelli","year":"2006","journal-title":"JOP"},{"issue":"2","key":"10.1016\/j.yasu.2025.04.011_bib2","doi-asserted-by":"crossref","first-page":"223","DOI":"10.3748\/wjg.v29.i2.223","article-title":"Irreversible electroporation for the management of pancreatic cancer: current data and future directions","volume":"29","author":"Spiliopoulos","year":"2023","journal-title":"World J Gastroenterol"},{"issue":"6","key":"10.1016\/j.yasu.2025.04.011_bib3","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1016\/j.suc.2016.07.010","article-title":"Management of locally advanced pancreatic cancer","volume":"96","author":"Martin","year":"2016","journal-title":"Surg Clin North Am"},{"issue":"11","key":"10.1016\/j.yasu.2025.04.011_bib4","doi-asserted-by":"crossref","first-page":"3157","DOI":"10.3748\/wjg.v21.i11.3157","article-title":"Update on the management of pancreatic cancer: surgery is not enough","volume":"21","author":"Ansari","year":"2015","journal-title":"World J Gastroenterol"},{"issue":"1","key":"10.1016\/j.yasu.2025.04.011_bib5","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1159\/000347178","article-title":"Pancreatic cancer: advances in treatment, results and limitations","volume":"31","author":"Hackert","year":"2013","journal-title":"Dig Dis"},{"issue":"1","key":"10.1016\/j.yasu.2025.04.011_bib6","doi-asserted-by":"crossref","DOI":"10.3390\/cancers10010016","article-title":"Locally advanced pancreatic cancer: a review of local ablative therapies","volume":"10","author":"Ruarus","year":"2018","journal-title":"Cancers (Basel)"},{"issue":"6","key":"10.1016\/j.yasu.2025.04.011_bib7","first-page":"588","article-title":"Radiofrequency ablation of the pancreas. II: intra-operative ablation of non-resectable pancreatic cancer. A description of technique and initial outcome","volume":"6","author":"Date","year":"2005","journal-title":"JOP : J Pancreas"},{"issue":"1","key":"10.1016\/j.yasu.2025.04.011_bib8","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1080\/02656736.2018.1506165","article-title":"Thermal ablation of pancreatic cancer: a systematic literature review of clinical practice and pre-clinical studies","volume":"35","author":"Saccomandi","year":"2018","journal-title":"Int J Hyperther"},{"issue":"11","key":"10.1016\/j.yasu.2025.04.011_bib9","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13112511","article-title":"Ablation in pancreatic cancer: past, present and future","volume":"13","author":"Narayanan","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.yasu.2025.04.011_bib10","article-title":"Optimizing patient selection for irreversible electroporation of locally advanced pancreatic cancer: analyses of survival","volume":"11","author":"Woeste","year":"2021","journal-title":"Front Oncol"},{"issue":"2","key":"10.1016\/j.yasu.2025.04.011_bib11","doi-asserted-by":"crossref","first-page":"167","DOI":"10.6004\/jnccn.2014.0017","article-title":"Evolving treatment options for locally advanced unresectable pancreatic ductal adenocarcinoma","volume":"12","author":"Cinar","year":"2014","journal-title":"J Natl Compr Cancer Netw"},{"issue":"6","key":"10.1016\/j.yasu.2025.04.011_bib12","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/S1470-2045(16)00172-8","article-title":"FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis","volume":"17","author":"Suker","year":"2016","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.yasu.2025.04.011_bib13","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1097\/SLA.0000000000002600","article-title":"Predictors of resectability and survival in patients with borderline and locally advanced pancreatic cancer who underwent neoadjuvant treatment with FOLFIRINOX","volume":"269","author":"Michelakos","year":"2019","journal-title":"Ann Surg"},{"issue":"4","key":"10.1016\/j.yasu.2025.04.011_bib52","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1055\/a-1178-0474","article-title":"US-Guided percutaneous radiofrequency ablation of locally advanced pancreatic adenocarcinoma: a 5-year high-volume center experience","volume":"43","author":"D\u2019Onofrio","year":"2022","journal-title":"Ultraschall Med"},{"issue":"2","key":"10.1016\/j.yasu.2025.04.011_bib53","doi-asserted-by":"crossref","first-page":"6","DOI":"10.4251\/wjgo.v7.i2.6","article-title":"Radiofrequency ablation of pancreatic ductal adenocarcinoma: the past, the present and the future","volume":"7","author":"Pandya","year":"2015","journal-title":"World J Gastrointest Oncol"},{"issue":"2","key":"10.1016\/j.yasu.2025.04.011_bib54","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s00270-011-0189-8","article-title":"Microwave ablation with percutaneous approach for the treatment of pancreatic adenocarcinoma","volume":"35","author":"Carrafiello","year":"2012","journal-title":"Cardiovasc Interv Radiol"},{"issue":"2","key":"10.1016\/j.yasu.2025.04.011_bib55","doi-asserted-by":"crossref","first-page":"741","DOI":"10.4081\/cp.2015.741","article-title":"Computed tomography-guided cryoablation of local recurrence after primary resection of pancreatic adenocarcinoma","volume":"5","author":"Pusceddu","year":"2015","journal-title":"Clin Pract"},{"issue":"7","key":"10.1016\/j.yasu.2025.04.011_bib14","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1016\/j.pan.2021.08.002","article-title":"Open irreversible electroporation for isolated local recurrence of pancreatic ductal adenocarcinoma after primary surgery","volume":"21","author":"Heger","year":"2021","journal-title":"Pancreatology"},{"issue":"3","key":"10.1016\/j.yasu.2025.04.011_bib15","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.jamcollsurg.2012.05.021","article-title":"Irreversible electroporation therapy in the management of locally advanced pancreatic adenocarcinoma. Clinical Trial Multicenter Study","volume":"215","author":"Martin","year":"2012","journal-title":"J Am Coll Surg"},{"issue":"1","key":"10.1016\/j.yasu.2025.04.011_bib16","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1002\/jso.21899","article-title":"Irreversible electroporation of the pancreas: definitive local therapy without systemic effects. Research Support, Non-U.S. Gov\u2019t","volume":"104","author":"Bower","year":"2011","journal-title":"J Surg Oncol"},{"issue":"3","key":"10.1016\/j.yasu.2025.04.011_bib17","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1097\/SLA.0000000000001441","article-title":"Treatment of 200 locally advanced (stage III) pancreatic adenocarcinoma patients with irreversible electroporation: safety and efficacy","volume":"262","author":"Martin","year":"2015","journal-title":"Ann Surg"},{"issue":"Suppl 3","key":"10.1016\/j.yasu.2025.04.011_bib18","doi-asserted-by":"crossref","first-page":"S443","DOI":"10.1245\/s10434-012-2736-1","article-title":"Irreversible electroporation in locally advanced pancreatic cancer: potential improved overall survival. Research Support, Non-U.S. Gov\u2019t","volume":"20","author":"Martin","year":"2013","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"10.1016\/j.yasu.2025.04.011_bib19","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1097\/SLA.0000000000001441","article-title":"Treatment of 200 locally advanced (stage III) pancreatic adenocarcinoma patients with irreversible electroporation: safety and efficacy","volume":"262","author":"Martin","year":"2015","journal-title":"Ann Surg"},{"issue":"8","key":"10.1016\/j.yasu.2025.04.011_bib20","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/j.hpb.2018.12.004","article-title":"A prospective, multi-institution assessment of irreversible electroporation for treatment of locally advanced pancreatic adenocarcinoma: initial outcomes from the AHPBA pancreatic registry","volume":"21","author":"Holland","year":"2019","journal-title":"HPB (Oxford)"},{"issue":"11","key":"10.1016\/j.yasu.2025.04.011_bib21","doi-asserted-by":"crossref","first-page":"4348","DOI":"10.1245\/s10434-020-08782-2","article-title":"Electrochemotherapy with irreversible electroporation and FOLFIRINOX improves survival in murine models of pancreatic adenocarcinoma","volume":"27","author":"Bhutiani","year":"2020","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"10.1016\/j.yasu.2025.04.011_bib22","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1002\/jso.24288","article-title":"Irreversible electroporation enhances delivery of gemcitabine to pancreatic adenocarcinoma","volume":"114","author":"Bhutiani","year":"2016","journal-title":"J Surg Oncol"},{"issue":"8","key":"10.1016\/j.yasu.2025.04.011_bib23","article-title":"Optimal dosing and patient selection for electrochemotherapy in solid abdominal organ and bone tumors","volume":"10","author":"Martin","year":"2023","journal-title":"Bioengineering (Basel)"},{"issue":"3","key":"10.1016\/j.yasu.2025.04.011_bib24","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.jamcollsurg.2012.05.021","article-title":"Irreversible electroporation therapy in the management of locally advanced pancreatic adenocarcinoma","volume":"215","author":"Martin","year":"2012","journal-title":"J Am Coll Surg"},{"key":"10.1016\/j.yasu.2025.04.011_bib25","doi-asserted-by":"crossref","first-page":"80","DOI":"10.21037\/tgh.2018.10.05","article-title":"Palliative therapy in pancreatic cancer-interventional treatment with radiofrequency ablation\/irreversible electroporation","volume":"3","author":"Paiella","year":"2018","journal-title":"Transl Gastroenterol Hepatol"},{"issue":"11","key":"10.1016\/j.yasu.2025.04.011_bib26","doi-asserted-by":"crossref","first-page":"6201","DOI":"10.1245\/s10434-021-10174-z","article-title":"An improved staging system for locally advanced pancreatic cancer: a critical need in the multidisciplinary era","volume":"28","author":"Fromer","year":"2021","journal-title":"Ann Surg Oncol"},{"issue":"6","key":"10.1016\/j.yasu.2025.04.011_bib27","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1093\/bja\/aeu256","article-title":"Anaesthetic management during open and percutaneous irreversible electroporation","volume":"113","author":"Nielsen","year":"2014","journal-title":"Br J Anaesth"},{"issue":"10","key":"10.1016\/j.yasu.2025.04.011_bib28","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1007\/s11605-013-2309-z","article-title":"Irreversible electroporation of locally advanced pancreatic head adenocarcinoma","volume":"17","author":"Martin","year":"2013","journal-title":"J Gastrointest Surg"},{"issue":"3","key":"10.1016\/j.yasu.2025.04.011_bib29","first-page":"329","article-title":"Irreversible electroporation of locally advanced pancreatic neck\/body adenocarcinoma","volume":"6","author":"Martin","year":"2015","journal-title":"J Gastrointest Oncol"},{"issue":"3","key":"10.1016\/j.yasu.2025.04.011_bib30","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1002\/jso.26041","article-title":"Cardiac synchronization and arrhythmia during irreversible electroporation","volume":"122","author":"O\u2019Neill","year":"2020","journal-title":"J Surg Oncol"},{"issue":"2","key":"10.1016\/j.yasu.2025.04.011_bib31","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.jamcollsurg.2013.10.013","article-title":"Evaluation of resistance as a measure of successful tumor ablation during irreversible electroporation of the pancreas","volume":"218","author":"Dunki-Jacobs","year":"2014","journal-title":"J Am Coll Surg"},{"key":"10.1016\/j.yasu.2025.04.011_bib32","first-page":"4","article-title":"Irreversible electroporation of stage 3 locally advanced pancreatic cancer: optimal technique and outcomes","volume":"1","author":"Martin","year":"2015","journal-title":"J Vis Surg"},{"issue":"2","key":"10.1016\/j.yasu.2025.04.011_bib33","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s10439-005-8981-8","article-title":"Tissue ablation with irreversible electroporation","volume":"33","author":"Davalos","year":"2005","journal-title":"Ann Biomed Eng"},{"issue":"7","key":"10.1016\/j.yasu.2025.04.011_bib34","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1002\/jso.24404","article-title":"Irreversible electroporation in locally advanced pancreatic cancer: a call for standardization of energy delivery","volume":"114","author":"Martin","year":"2016","journal-title":"J Surg Oncol"},{"issue":"3","key":"10.1016\/j.yasu.2025.04.011_bib35","first-page":"211","article-title":"Use of irreversible electroporation in unresectable pancreatic cancer","volume":"4","author":"Martin","year":"2015","journal-title":"Hepatobiliary Surg Nutr"},{"issue":"11","key":"10.1016\/j.yasu.2025.04.011_bib36","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0076260","article-title":"Irreversible electroporation ablation (IRE) of unresectable soft tissue tumors: learning curve evaluation in the first 150 patients treated. Research Support, Non-U.S. Gov\u2019t","volume":"8","author":"Philips","year":"2013","journal-title":"PLoS One"},{"issue":"9","key":"10.1016\/j.yasu.2025.04.011_bib37","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.diii.2017.07.007","article-title":"Irreversible electroporation and thermal ablation of tumors in the liver, lung, kidney and bone: what are the differences?","volume":"98","author":"Vroomen","year":"2017","journal-title":"Diagn Interv Imaging"},{"issue":"5","key":"10.1016\/j.yasu.2025.04.011_bib38","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1002\/jso.23280","article-title":"Safety and early efficacy of irreversible electroporation for hepatic tumors in proximity to vital structures","volume":"107","author":"Cannon","year":"2013","journal-title":"J Surg Oncol"},{"issue":"3","key":"10.1016\/j.yasu.2025.04.011_bib39","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.surg.2022.07.033","article-title":"Impact of margin accentuation with intraoperative irreversible electroporation on local recurrence in resected pancreatic cancer","volume":"173","author":"Martin","year":"2023","journal-title":"Surgery"},{"issue":"Suppl 3","key":"10.1016\/j.yasu.2025.04.011_bib40","doi-asserted-by":"crossref","first-page":"S443","DOI":"10.1245\/s10434-012-2736-1","article-title":"Irreversible electroporation in locally advanced pancreatic cancer: potential improved overall survival","volume":"20","author":"Martin","year":"2013","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"10.1016\/j.yasu.2025.04.011_bib78","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1177\/0284185120917118","article-title":"Initial experience of irreversible electroporation for locally advanced pancreatic cancer in a Korean population","volume":"62","author":"Kwon","year":"2021","journal-title":"Acta Radiol"},{"key":"10.1016\/j.yasu.2025.04.011_bib75","doi-asserted-by":"crossref","first-page":"622318","DOI":"10.3389\/fonc.2020.622318","article-title":"Survival comparison of neoadjuvant chemotherapy followed by irreversible electroporation versus conversional Rresection for locally advanced pancreatic cancer","volume":"10","author":"He","year":"2021","journal-title":"Front Oncol"},{"issue":"22","key":"10.1016\/j.yasu.2025.04.011_bib56","doi-asserted-by":"crossref","first-page":"5564","DOI":"10.12998\/wjcc.v8.i22.5564","article-title":"Gemcitabine plus concurrent irreversible electroporation vs gemcitabine alone for locally advanced pancreatic cancer","volume":"8","author":"Ma","year":"2020","journal-title":"World J Clin Cases"},{"issue":"2","key":"10.1016\/j.yasu.2025.04.011_bib79","doi-asserted-by":"crossref","first-page":"280","DOI":"10.4103\/jcrt.JCRT_773_18","article-title":"Irreversible electroporation and adjuvant chemoradiotherapy for locally advanced pancreatic carcinoma","volume":"16","author":"Xu","year":"2020","journal-title":"J Cancer Res Ther"},{"issue":"1","key":"10.1016\/j.yasu.2025.04.011_bib83","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.hbpd.2021.06.004","article-title":"Irreversible electroporation plus chemotherapy versus chemotherapy alone as treatments for patients with locally advanced pancreatic cancer","volume":"21","author":"Liu","year":"2022","journal-title":"Hepatobiliary Pancreat Dis Int"},{"issue":"22","key":"10.1016\/j.yasu.2025.04.011_bib81","doi-asserted-by":"crossref","first-page":"3225","DOI":"10.2169\/internalmedicine.0861-18","article-title":"Irreversible electroporation for nonthermal tumor ablation in patients with locally advanced pancreatic cancer: initial clinical experience in Japan","volume":"57","author":"Sugimoto","year":"2018","journal-title":"Intern Med"},{"issue":"9","key":"10.1016\/j.yasu.2025.04.011_bib61","doi-asserted-by":"crossref","first-page":"2734","DOI":"10.1245\/s10434-017-5900-9","article-title":"Induction chemotherapy followed by resection or irreversible electroporation in locally advanced pancreatic cancer (IMPALA): a prospective cohort study","volume":"24","author":"Vogel","year":"2017","journal-title":"Ann Surg Oncol"},{"issue":"24","key":"10.1016\/j.yasu.2025.04.011_bib84","doi-asserted-by":"crossref","first-page":"2920","DOI":"10.4103\/0366-6999.195476","article-title":"A aingle-institution experience with open irreversible electroporation for locally advanced pancreatic carcinoma","volume":"129","author":"Yan","year":"2016","journal-title":"Chin Med J (Engl)"},{"issue":"1","key":"10.1016\/j.yasu.2025.04.011_bib60","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/jso.25110","article-title":"The efficacy of combination of induction chemotherapy and irreversible electroporation ablation for patients with locally advanced pancreatic adenocarcinoma","volume":"118","author":"Huang","year":"2018","journal-title":"J Surg Oncol"},{"issue":"1","key":"10.1016\/j.yasu.2025.04.011_bib80","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1148\/radiol.2019191109","article-title":"Percutaneous irreversible electroporation in locally advanced and recurrent pancreatic cancer (PANFIRE-2): a multicenter, prospective, single-arm, phase II study","volume":"294","author":"Ruarus","year":"2020","journal-title":"Radiology"},{"issue":"3","key":"10.1016\/j.yasu.2025.04.011_bib76","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1007\/s12029-020-00425-9","article-title":"Irreversible electroporation in locally advanced pancreatic adenocarcinoma: aiming to improve overall survival","volume":"51","author":"Enjuto","year":"2020","journal-title":"J Gastrointest Cancer"},{"issue":"2","key":"10.1016\/j.yasu.2025.04.011_bib77","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1080\/00365521.2019.1575465","article-title":"Treatment of locally advanced pancreatic cancer with irreversible electroporation - a Danish single center study of safety and feasibility","volume":"54","author":"Flak","year":"2019","journal-title":"Scand J Gastroenterol"},{"issue":"9","key":"10.1016\/j.yasu.2025.04.011_bib85","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1016\/j.ejso.2016.01.024","article-title":"Percutaneous irreversible electroporation for treatment of locally advanced pancreatic cancer following chemotherapy or radiochemotherapy","volume":"42","author":"M\u00e5nsson","year":"2016","journal-title":"Eur J Surg Oncol"},{"issue":"2","key":"10.1016\/j.yasu.2025.04.011_bib82","doi-asserted-by":"crossref","first-page":"275","DOI":"10.21037\/jgo.2018.01.14","article-title":"Percutaneous irreversible electroporation with systemic treatment for locally advanced pancreatic adenocarcinoma","volume":"9","author":"Leen","year":"2018","journal-title":"J Gastrointest Oncol"},{"issue":"2","key":"10.1016\/j.yasu.2025.04.011_bib86","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1148\/radiol.2016152835","article-title":"Ablation of locally advanced pancreatic cancer with percutaneous irreversible electroporation: results of the phase I\/II PANFIRE study","volume":"282","author":"Scheffer","year":"2017","journal-title":"Radiology"},{"issue":"3","key":"10.1016\/j.yasu.2025.04.011_bib87","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.jvir.2016.10.023","article-title":"Percutaneous image-guided irreversible electroporation for the treatment of unresectable, locally advanced pancreatic adenocarcinoma","volume":"28","author":"Narayanan","year":"2017","journal-title":"J Vasc Interv Radiol"},{"issue":"3","key":"10.1016\/j.yasu.2025.04.011_bib88","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1007\/s12032-017-0887-4","article-title":"Concurrent chemotherapy alone versus irreversible electroporation followed by chemotherapy on survival in patients with locally advanced pancreatic cancer","volume":"34","author":"Belfiore","year":"2017","journal-title":"Med Oncol"},{"issue":"5","key":"10.1016\/j.yasu.2025.04.011_bib90","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1245\/s10434-015-5034-x","article-title":"Single-institution experience with irreversible electroporation for T4 pancreatic cancer: first 50 patients","volume":"23","author":"Kluger","year":"2016","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"10.1016\/j.yasu.2025.04.011_bib89","first-page":"269","article-title":"Treatment of locally advanced pancreatic cancer by percutaneous and intraoperative irreversible electroporation: general hospital cancer center experience","volume":"63","author":"Lambert","year":"2016","journal-title":"Neoplasma"},{"issue":"2","key":"10.1016\/j.yasu.2025.04.011_bib91","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1159\/000375323","article-title":"Safety and feasibility of Irreversible Electroporation (IRE) in patients with locally advanced pancreatic cancer: results of a prospective study","volume":"32","author":"Paiella","year":"2015","journal-title":"Dig Surg"},{"issue":"3","key":"10.1016\/j.yasu.2025.04.011_bib41","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/j.surg.2023.08.042","article-title":"Multi-institutional review of adverse events associated with irreversible electroporation in the treatment of locally advanced pancreatic cancer","volume":"175","author":"Stephens","year":"2024","journal-title":"Surgery"},{"issue":"4","key":"10.1016\/j.yasu.2025.04.011_bib42","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1002\/jso.27310","article-title":"Infection reporting in patients undergoing irreversible electroporation of locally advanced pancreatic cancer","volume":"128","author":"Filson","year":"2023","journal-title":"J Surg Oncol"},{"issue":"3","key":"10.1016\/j.yasu.2025.04.011_bib43","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.amjsurg.2019.03.020","article-title":"Quality of life assessment for patients undergoing irreversible electroporation (IRE) for treatment of locally advanced pancreatic cancer (LAPC)","volume":"218","author":"Field","year":"2019","journal-title":"Am J Surg"},{"issue":"7","key":"10.1016\/j.yasu.2025.04.011_bib44","first-page":"325","article-title":"Irreversible electroporation (IRE) combined with chemotherapy increases survival in locally advanced pancreatic cancer (LAPC)","volume":"44","author":"Oikonomou","year":"2021","journal-title":"Am J Clin Oncol-Cancer Clin Trials"},{"issue":"3","key":"10.1016\/j.yasu.2025.04.011_bib57","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.pan.2020.02.009","article-title":"Irreversible electroporation after induction chemotherapy versus chemotherapy alone for patients with locally advanced pancreatic cancer: a propensity score matching analysis","volume":"20","author":"He","year":"2020","journal-title":"Pancreatology"},{"key":"10.1016\/j.yasu.2025.04.011_bib58","doi-asserted-by":"crossref","first-page":"6","DOI":"10.3389\/fonc.2020.00006","article-title":"Comparison of survival between irreversible electroporation followed by chemotherapy and chemotherapy alone for locally advanced pancreatic cancer","volume":"10","author":"He","year":"2020","journal-title":"Front Oncol"},{"issue":"10","key":"10.1016\/j.yasu.2025.04.011_bib59","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1016\/j.jvir.2020.02.024","article-title":"Value of CT-guided percutaneous irreversible electroporation added to FOLFIRINOX chemotherapy in locally advanced pancreatic cancer: a post hoc comparison","volume":"31","author":"van Veldhuisen","year":"2020","journal-title":"J Vasc Intervent Radiol"},{"issue":"3","key":"10.1016\/j.yasu.2025.04.011_bib69","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1177\/15533506231157442","article-title":"Irreversible electroporation-assisted resection for locally advanced pancreas cancer","volume":"30","author":"Davis","year":"2023","journal-title":"Surg Innov"},{"issue":"10","key":"10.1016\/j.yasu.2025.04.011_bib70","doi-asserted-by":"crossref","first-page":"2571","DOI":"10.1016\/j.ejso.2021.05.024","article-title":"Margin accentuation for resectable pancreatic cancer using irreversible electroporation - results from the MACPIE-I study","volume":"47","author":"Kundalia","year":"2021","journal-title":"Eur J Surg Oncol"},{"issue":"7","key":"10.1016\/j.yasu.2025.04.011_bib71","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1007\/s11517-016-1603-9","article-title":"Irreversible electroporation as treatment of locally advanced and as margin accentuation in borderline resectable pancreatic adenocarcinoma","volume":"55","author":"Marsanic","year":"2017","journal-title":"Med Biol Eng Comput"},{"issue":"4","key":"10.1016\/j.yasu.2025.04.011_bib72","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1016\/j.surg.2014.06.058","article-title":"Borderline and locally advanced pancreatic adenocarcinoma margin accentuation with intraoperative irreversible electroporation","volume":"156","author":"Kwon","year":"2014","journal-title":"Surgery"},{"issue":"12","key":"10.1016\/j.yasu.2025.04.011_bib73","doi-asserted-by":"crossref","first-page":"8298","DOI":"10.1245\/s10434-024-15962-x","article-title":"Irreversible electroporation margin accentuation in pancreaticoduodenectomy: a propensity score matching analysis","volume":"31","author":"Lim","year":"2024","journal-title":"Ann Surg Oncol"},{"issue":"8","key":"10.1016\/j.yasu.2025.04.011_bib45","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1002\/jso.27085","article-title":"Long-term follow-up experience with adjuvant therapy after irreversible electroporation of locally advanced pancreatic cancer","volume":"126","author":"Thomas","year":"2022","journal-title":"J Surg Oncol"},{"key":"10.1016\/j.yasu.2025.04.011_bib46","doi-asserted-by":"crossref","DOI":"10.1007\/s00330-024-10613-x","article-title":"Irreversible electroporation to bring initially unresectable locally advanced pancreatic adenocarcinoma to surgery: the IRECAP phase II study","author":"Tasu","year":"2024","journal-title":"Eur Radiol"},{"key":"10.1016\/j.yasu.2025.04.011_bib47","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.712042","article-title":"Immunomodulatory effect of irreversible electroporation alone and its cooperating with immunotherapy in pancreatic cancer","volume":"11","author":"Tian","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.yasu.2025.04.011_bib48","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1193040","article-title":"Irreversible electroporation combined with chemotherapy and PD-1\/PD-L1 blockade enhanced antitumor immunity for locally advanced pancreatic cancer","volume":"14","author":"Ma","year":"2023","journal-title":"Front Immunol"},{"issue":"10","key":"10.1016\/j.yasu.2025.04.011_bib62","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1016\/j.jvir.2023.06.027","article-title":"Tissue resistance decrease during irreversible electroporation of pancreatic cancer as a biomarker for the adaptive immune response and survival","volume":"34","author":"Timmer","year":"2023","journal-title":"J Vasc Intervent Radiol"},{"key":"10.1016\/j.yasu.2025.04.011_bib63","doi-asserted-by":"crossref","first-page":"4795","DOI":"10.2147\/JIR.S331023","article-title":"Irreversible electroporation plus anti-PD-1 antibody versus irreversible electroporation alone for patients with locally advanced pancreatic cancer","volume":"14","author":"He","year":"2021","journal-title":"J Inflamm Res"},{"issue":"15","key":"10.1016\/j.yasu.2025.04.011_bib64","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13153902","article-title":"Irreversible electroporation and nivolumab combined with intratumoral administration of a toll-like receptor ligand, as a means of in vivo vaccination for metastatic pancreatic ductal adenocarcinoma (PANFIRE-III). A phase-i study protocol","volume":"13","author":"Geboers","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"3","key":"10.1016\/j.yasu.2025.04.011_bib65","first-page":"1643","article-title":"Efficacy of irreversible electroporation ablation combined with natural killer cells in treating locally advanced pancreatic cancer","volume":"25","author":"Pan","year":"2020","journal-title":"J BUON"},{"issue":"4","key":"10.1016\/j.yasu.2025.04.011_bib66","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.surg.2020.04.057","article-title":"A phase 1b trial of concurrent immunotherapy and irreversible electroporation in the treatment of locally advanced pancreatic adenocarcinoma","volume":"168","author":"O\u2019Neill","year":"2020","journal-title":"Surgery"},{"issue":"1","key":"10.1016\/j.yasu.2025.04.011_bib67","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/s41392-020-00260-1","article-title":"Irreversible electroporation plus allogenic Vgamma9Vdelta2 T cells enhances antitumor effect for locally advanced pancreatic cancer patients","volume":"5","author":"Lin","year":"2020","journal-title":"Signal Transduct Targeted Ther"},{"issue":"11","key":"10.1016\/j.yasu.2025.04.011_bib68","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2019.1652532","article-title":"Irreversible electroporation of locally advanced pancreatic cancer transiently alleviates immune suppression and creates a window for antitumor T cell activation","volume":"8","author":"Scheffer","year":"2019","journal-title":"OncoImmunology"},{"issue":"1","key":"10.1016\/j.yasu.2025.04.011_bib49","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1038\/s41467-019-08782-1","article-title":"Irreversible electroporation reverses resistance to immune checkpoint blockade in pancreatic cancer","volume":"10","author":"Zhao","year":"2019","journal-title":"Nat Commun"},{"issue":"4","key":"10.1016\/j.yasu.2025.04.011_bib50","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-006221","article-title":"Irreversible electroporation augments beta-glucan induced trained innate immunity for the treatment of pancreatic ductal adenocarcinoma","volume":"11","author":"Woeste","year":"2023","journal-title":"J Immunother Cancer"},{"issue":"1","key":"10.1016\/j.yasu.2025.04.011_bib51","first-page":"165","article-title":"Perioperative systemic immunophenotype following irreversible electroporation (IRE) predicts recurrence","volume":"12","author":"O\u2019Neill","year":"2022","journal-title":"Am J Cancer Res"}],"container-title":["Advances in Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0065341125000119?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0065341125000119?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T22:09:45Z","timestamp":1754431785000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0065341125000119"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":90,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S0065341125000119"],"URL":"https:\/\/doi.org\/10.1016\/j.yasu.2025.04.011","relation":{},"ISSN":["0065-3411"],"issn-type":[{"value":"0065-3411","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"What Is the Role of Irreversible Electroporation for Pancreatic Cancer?","name":"articletitle","label":"Article Title"},{"value":"Advances in Surgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yasu.2025.04.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}